Trident Lifeline Limited now holds a 58.67% stake in its subsidiary, Trident Mediquip Limited, following a private placement of equity shares to other shareholders. The reduction from a previous holding of 58.84% was disclosed to the exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transaction is classified as a related party transaction but was executed on an arm's length basis.

Trident Mediquip Limited, incorporated on October 19, 2019, operates within the medical device industry. The subsidiary has an authorized and paid-up share capital of ₹10,00,00,000, divided into 1,00,00,000 equity shares of ₹10 each. The entity is based in Surat, Gujarat, and its operations are entirely domestic.

The filing confirmed that the private placement involved the allotment of shares to other shareholders, which diluted the parent company's stake. Promoters and promoter group members, including Mr. Amit Bhupendra Halvawala and Mr. Chetan Chandrakant Jariwala, hold interests in the subsidiary. The company stated that no specific governmental or regulatory approvals were required for this acquisition.

Financial Performance of Trident Mediquip

The subsidiary has demonstrated consistent revenue growth over the past three financial years. The turnover figures for the last three years are as follows:

The disclosure was submitted by Nikita Sharma, Company Secretary and Compliance Officer of Trident Lifeline Limited, on June 16, 2026.

Trident Lifeline Limited has published the newspaper advertisement for its postal ballot notice regarding the appointment of two independent directors and the migration of its securities from the BSE SME platform to the main boards of BSE Limited and National Stock Exchange of India Limited. The advertisement appeared in the Financial Express in both English and Gujarati editions on June 15, 2026. This initiative aims to strengthen corporate governance and expand market access for the company's equity shares, which have a face value of ₹10.00 each.

The Board of Directors approved the appointment of Ms. Smita Kiran Davda and Mr. Sachin Bhandari as Non-Executive Independent Directors during a meeting held on June 13, 2026. Ms. Davda, a Fellow Chartered Accountant, brings experience in banking and finance, while Mr. Bhandari offers expertise in the pharmaceutical industry and regulatory compliance. Both appointees are unrelated to existing directors and are not debarred from holding the directorship. Their appointments are subject to shareholder approval via special resolution for a term of five consecutive years from June 13, 2026, to June 12, 2031.

The company has fixed Friday, June 05, 2026, as the record date to determine shareholder eligibility for voting. The remote e-voting period commences at 09:00 A.M. IST on Tuesday, June 15, 2026, and concludes at 05:00 P.M. IST on Wednesday, July 15, 2026. The results of the postal ballot are expected to be declared on or before Friday, July 17, 2026, at the registered office of the company in Surat.

Migration to Main Board

The migration from the BSE SME platform to the main boards of BSE Limited and National Stock Exchange of India Limited is subject to the approval of members, stock exchanges, and other relevant authorities under Chapter IX of the SEBI (ICDR) Regulations, 2018. The resolution requires that votes cast by public shareholders in favour must be at least two times the votes cast against the proposal.

Postal Ballot and E-Voting

National Securities Depository Limited (NSDL) has been appointed as the Remote E-Voting Agency. Ms. Mittalben Vaikunthbhai Kothari, Proprietor of M/s. Mittal V Kothari & Associates, has been appointed as the scrutinizer. Shareholders can cast their votes electronically through the NSDL e-voting website or via their depository accounts. The postal ballot notice was dispatched electronically on June 15, 2026, and is available on the company's website.

Key Appointments Details